Clinical Trial

Predictors of Androgen Status Decline in Middle-Aged Men

Study acronym: TESMEN
Recruiting
View on ClinicalTrials.gov →
Summary
Decreased testosterone levels in middle-aged men are associated with multiple metabolic, functional and psychosocial consequences. Early identification of modifiable factors associated with reduced testosterone levels may facilitate the early identification of men at increased risk of testosterone deficiency and support preventive healthcare strategies. This population-based cross-sectional observational study aims to investigate anthropometric, functional and lifestyle-related factors associated with serum total testosterone levels in middle-aged men. Approximately 600 men aged 35-59 years residing in the Andijan region of Uzbekistan will be recruited. Participants will undergo comprehensive assessment including anthropometric measurements, functional performance tests, standardised questionnaires and laboratory determination of serum total testosterone concentrations. Anthropometric variables will include body mass index, waist circumference, hip circumference, waist-to-hip ratio and waist-to-height ratio. Functional status will be assessed using hand-grip strength, the five-times chair-stand test and the 4-m walk test. Lifestyle-related factors including physical activity, sleep quality, dietary habits, smoking, alcohol consumption and psychoemotional status will be evaluated using validated questionnaires. The study aims to identify factors associated with serum total testosterone levels and to develop a predictive model for the early identification of men at increased risk of testosterone deficiency.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-10
notable Enrollment reduced: 800 -> 600 participants 2026-05-19
Trial Details
NCT Number NCT07476222
Lead Sponsor Andijan State Medical Institute
Collaborators: Tashkent Medical Academy
Conditions Testosterone Deficiency, Androgen Deficiency, Male Hypogonadism, Late-Onset Hypogonadism
Enrollment 600 participants
Start Date 2026-06-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-31